Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 1;14(5):1276.
doi: 10.3390/cancers14051276.

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Adrian Minson  1   2 , Constantine Tam  1   2 , Michael Dickinson  1   2 , John F Seymour  1   2
Affiliations
Review

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Adrian Minson et al. Cancers (Basel). .

Abstract

Targeted therapies continue to change the landscape of lymphoma treatment, resulting in improved therapy options and patient outcomes. Numerous agents are now approved for use in the indolent lymphomas and many others under development demonstrate significant promise. In this article, we review the landscape of targeted agents that apply to the indolent lymphomas, predominantly follicular lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia and marginal zone lymphoma. The review covers small molecule inhibitors, immunomodulators and targeted immunotherapies, as well as presenting emerging and promising combination therapies.

Keywords: immunotherapy; non-Hodgkin lymphoma; personalised medicine; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

J.F.S.: research funding Abbvie, BMS, Roche; advisory board/honoraria Abbie, Astra Zeneca, Beigene, BMS, Genentech, Genor Bio, Gilead, Janssen, Roche, Sunesis, TG Therapeutics. CT: research funding Beigene, Janssen, Abbvie; honoraria Beigene, Janssen, Abbvie. MD: research funding MSD, Celgene, Takeda, Roche, Novartis; advisory board/honoraria Roche, Amgen, MSD, Novartis, BMS, Gilead, Janssen. AM: reseach funding Roche, Novartis, Gilead.

Similar articles

See all similar articles

Cited by

References

    1. Kipps T.J., Choi M.Y. Targeted Therapy in Chronic Lymphocytic Leukemia. Cancer J. 2019;25:378–385. doi: 10.1097/PPO.0000000000000416. - DOI - PMC - PubMed
    1. Kipps T.J., Stevenson F.K., Wu C.J., Croce C.M., Packham G., Wierda W.G., O’Brien S., Gribben J., Rai K. Chronic lymphocytic leukaemia. Nat. Rev. Dis. Primers. 2017;3:16096. doi: 10.1038/nrdp.2016.96. - DOI - PMC - PubMed
    1. Woyach J.A., Johnson A.J. Targeted therapies in CLL: Mechanisms of resistance and strategies for management. Blood. 2015;126:471–477. doi: 10.1182/blood-2015-03-585075. - DOI - PMC - PubMed
    1. Hanel W., Epperla N. Emerging therapies in mantle cell lymphoma. J. Hematol. Oncol. 2020;13:79. doi: 10.1186/s13045-020-00914-1. - DOI - PMC - PubMed
    1. Buege M.J., Kumar A., Dixon B.N., Tang L.A., Pak T., Orozco J., Peterson T.J., Maples K.T. Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Ann. Pharmacother. 2020;54:879–898. doi: 10.1177/1060028020909117. - DOI - PMC - PubMed

LinkOut - more resources